ART Advanced Research Technologies Translational Imaging Platform Showcased at the World Molecular Imaging Congress in Montreal,
21 September 2009 - 11:31PM
Marketwired
ART Advanced Research Technologies Inc. ("ART") (TSX: ARA), a
Canadian medical device company and a leader in optical molecular
imaging products for the healthcare and pharmaceutical industries,
announced today that current research relating to its molecular
imaging products will be presented at poster sessions at the World
Molecular Imaging Congress (WMIC), being held at the Palais des
congres in Montreal, Canada, from September 23 to 26, 2009. ART is
also displaying its Optix®, SoftScan® and Fenestra® product
offering as an exhibitor at the event (booth #301), in the Exhibit
Hall of the Palais des congres.
Prior to the start of the meeting - on Tuesday, September 22 -
ART will hold a ART User Forum, where Optix users from major
pharmaceutical companies and research institutes will present their
work, and provide a hands-on opportunity for potential clients to
learn about new developments and applications available for the
Optix system, as well as the capability for translational research
using the SoftScan® breast imaging device. Both products are based
on the proprietary time domain technology developed by ART, which
allows for more accurate recovery of depth and concentration than
other optical systems.
About ART
ART Advanced Research Technologies Inc. is a leader in molecular
imaging products for the healthcare and pharmaceutical industries.
ART has developed products in medical imaging, medical diagnostics,
disease research, and drug discovery with the goal of bringing new
and better treatments to patients faster. The Optix® optical
molecular imaging system, designed for monitoring physiological
changes in living systems at the preclinical study phases of new
drugs, is used by industry and academic leaders worldwide. The
SoftScan® optical medical imaging device is designed to improve the
diagnosis and treatment of breast cancer. Finally, the Fenestra®
line of molecular imaging contrast products provides image
enhancement for a wide range of preclinical Micro CT applications
allowing scientists to see greater detail in their imaging studies,
with potential extension into other major imaging modalities. ART
is commercializing some of these products in a global strategic
alliance with GE Healthcare, a world leader in mammography and
imaging. ART's shares are listed on the TSX under the ticker symbol
ARA. For more information on ART, visit our website at
www.art.ca.
This press release may contain forward-looking statements
subject to risks and uncertainties that would cause actual events
to differ materially from expectations. These risks and
uncertainties are described in the most recent Annual Information
Form and the financial statements for the year ended December 31,
2008, available on SEDAR (www.sedar.com).
Contacts: ART Advanced Research Technologies Inc. Dino DiCamillo
Vice President, Global Sales and Marketing Preclinical Imaging
ddicamil@art.ca Jacques Bedard Chief Financial Officer 514-832-0777
jbedard@art.ca www.art.ca
Aclara Resources (TSX:ARA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Aclara Resources (TSX:ARA)
Historical Stock Chart
From Jul 2023 to Jul 2024